What is Champions Oncology, Inc.'s (CSBR) StockRank?

MoatMap's StockRank for Champions Oncology, Inc. (CSBR) is 30/100, with a Sell signal. This is a composite score combining Quality (58), Value (21), and Momentum (40) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Champions Oncology, Inc. have an economic moat?

Champions Oncology, Inc. (CSBR) has a Quality factor score of 58/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Champions Oncology, Inc. a buy, hold, or sell?

MoatMap's current signal for Champions Oncology, Inc. (CSBR) is Sell, based on a StockRank of 30/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Champions Oncology, Inc. in?

Champions Oncology, Inc. (CSBR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CSBR

SellFallen Favourite

Champions Oncology, Inc. · Healthcare · United States · $68M · Avg Vol: $52K/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-30.0%

D/E

1.1x

Dividend %

—

COMPANY DESCRIPTION

Champions Oncology, Inc. develops and sells advanced technology solutions and services to personalize the development and clinical use of oncology drugs. The company's proprietary TumorGraft platform utilizes patient-derived xenograft (PDX) models to predict patient responses to cancer therapies, establishing a strong moat in translational oncology. It is a leading niche provider of preclinical and clinical testing services for global pharmaceutical developers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	49.1M	53.9M	50.2M	56.9M	5.1%	59.4M
EPS	0.04	-0.39	-0.54	0.34	104.1%	-0.08
Shares	13.5M	13.5M	13.6M	13.7M	+1.4%	13.9M
Debt	9.5M	8.6M	7.4M	6.1M	-13.6%	4.6M
Equity	9.1M	4.6M	-1.9M	3.8M	-25.4%	—
Op CF	6.5M	4.0M	-6.1M	7.4M	4.4%	-4.5M
Inv CF	-2.4M	-2.9M	-0.8M	-0.4M	—	—
Fin CF	0.2M	11.0K	-0.5M	0.2M	—	—

Loading 1Y...

PRICE (1Y)-3.0%

SMA 50SMA 200

$5.10

RSI (14)

46.7

52W High

$8.74

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

57.1%99.0

ROE

-30.0%25.3

GP/Assets

88.2%97.1

Op. Margin

-3.8%30.3

FCF/Assets

n/mN/A

Piotroski

783.9

Int. Cover

—N/A

D/E Ratio

1.13x11.9

Current Ratio

0.96x10.3

Value

P/E (TTM)

—N/A

EV/EBITDA

208.0x2.4

P/FCF

n/mN/A

P/B

18.4x6.0

P/S

1.2x80.4

Div Yield

—N/A

Momentum

52W High %

58%34.4

RS 6M

-26%33.1

SMA 50/200

0.90x30.5

EPS Rev 4W

0.0%34.4

EPS Rev 12W

0.0%41.6

EPS Improve

+225%89.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$68M

P/E (Forward)

52.2x

Gross Margin

48.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CSBR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CSBR	Champions Oncology, Inc.(you)	$68M	30	Sell
INMB	INmune Bio Inc.	$65M	31	Sell
XBIT	XBiotech Inc.	$69M	27	Sell
APLM	Apollomics, Inc.	$77M	28	Sell
RNXT	RenovoRx, Inc.	$75M	26	Sell
ACRV	Acrivon Therapeutics, Inc.	$88M	29	Sell
BOLD	Boundless Bio, Inc.	$64M	36	Hold
MNOV	MediciNova, Inc.	$71M	23	Sell
PTHS	Pelthos Therapeutics Inc.	$95M	26	Sell
SEER	Seer, Inc.	$110M	28	Sell

Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%

Champions Oncology, Inc. (CSBR): Stock Score Summary

Champions Oncology, Inc. (CSBR) has a MoatMap StockRank of 30/100 based on Quality (58/100), Value (21/100), and Momentum (40/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$5.10
Market Cap	$68M
P/E (Forward)	52.20
Price/Book	18.38
Return on Equity	-30.0%
Return on Invested Capital	57.1%
Debt/Equity	1.13x
Gross Margin	48.0%
Operating Margin	-3.8%
Revenue Growth	12.0%
Free Cash Flow	$5M

Champions Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Champions Oncology, Inc.’s (CSBR) StockRank?: MoatMap’s StockRank for Champions Oncology, Inc. (CSBR) is 30/100, with a Sell signal. It is a composite of Quality (58), Value (21), and Momentum (40) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Champions Oncology, Inc. have an economic moat?: Champions Oncology, Inc. (CSBR) has a Quality factor score of 58/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Champions Oncology, Inc. a buy, hold, or sell?: MoatMap’s current signal for Champions Oncology, Inc. (CSBR) is Sell, based on a StockRank of 30/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Champions Oncology, Inc. in?: Champions Oncology, Inc. (CSBR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).